Beta-blocker drugs -- commonly used to treat heart and blood pressure issues -- may slow the progression of Huntington's disease (HD), according to a new study.
Novartis will make an upfront payment of $1.0 billion to PTCT and the latter will also be eligible for up to $1.9 billion in ...
Novartis licensed PTC's PTC518 Huntington's disease program and related molecules and will pay $1 billion upfront as well as other costs.
Stocktwits on MSN1d
PTC Therapeutics Stock Eyes Further Rally After Price-Target Hikes On Huntington’s Therapy Deal With Novartis: Retail Buzz GrowsShares of PTC Therapeutics Inc. climbed nearly 1% pre-market Tuesday, poised to extend their rally to levels last seen in ...
The potential $2.9 billion deal stands the New Jersey company in good stead after recent disappointing results in its ALS ...
PTC Therapeutics inks global license and collaboration agreement with Novartis for PTC518 Huntington's disease programme: Warren, New Jersey Tuesday, December 3, 2024, 14:00 Hrs [ ...
Basel: Novartis has announced that it has entered into a global license and collaboration agreement with PTC Therapeutics for ...
PTC Therapeutics Inc. said a “highly competitive process with several parties involved” led to the deal centered on the ...
The disease is characterized by progressive motor, cognitive, and psychiatric decline. Three treatments are approved to treat ...
Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged.
Novartis will partner with PTC Therapeutics to develop PTC’s PTC518 Huntington's disease program and an unspecified number of related molecules, through an up-to-$2.9 billion exclusive global license ...
RBC Capital has upgraded PTC Therapeutics (PTCT) to outperform from sector perform on the company’s deal with Novartis (NVS) for its Huntington’s disease program. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback